Acurx Pharmaceuticals Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Dave Luci
Chief executive officer
US$729.4k
Total compensation
| CEO salary percentage | 75.41% |
| CEO tenure | 8.4yrs |
| CEO ownership | 1.3% |
| Management average tenure | no data |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Antibiotic Resistance Threats And Funding Risks Will Eventually Reward This Microbiome Sparing Platform
Catalysts About Acurx Pharmaceuticals Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing DNA polymerase IIIC inhibitor antibiotics such as ibezapolstat for serious Gram positive bacterial infections including C. diff.Acurx Pharmaceuticals (NASDAQ:ACXP) Will Have To Spend Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Acurx Sell-Off Presents Opportunity Before Upcoming Data Release
Summary Acurx shares opened ~25% lower on Jan 17th, after releasing positive data suggesting its C. diff antibiotic outperformed standard treatment in restoring the gut microbiome. The decline in share price since then may be due to misaligned investor expectations regarding the release of sustained clinical cure rates. Acurx is expected to release additional data, including 94-day sustained clinical cure rates, which could further establish its antibiotic as a preferred treatment for C. diff. Read the full article on Seeking AlphaHere's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Is Acurx Pharmaceuticals (NASDAQ:ACXP) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Acurx, Pharmaceuticals drops 8.8%, announces $4.25M direct offering
Clinical-stage biopharmaceutical company, Acurx Pharmaceuticals (NASDAQ:ACXP) entered agreement with a single healthcare-focused U.S. institutional investor and certain executives of the company for the purchase and sale of an aggregate of 1.29M shares (which includes 130,769 pre-funded warrants) at $3.25 per share (or $3.2499 per pre-funded warrant) for the U.S. institutional investor and $3.80 per share for the company's executives. Gross proceeds are expected to be ~$4.225 M Closing is expected July 27, 2022. Stock down 8.8% during pre-market.Here's Why We're Watching Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Here's Why We're Not Too Worried About Acurx Pharmaceuticals' (NASDAQ:ACXP) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Companies Like Acurx Pharmaceuticals (NASDAQ:ACXP) Can Afford To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...New Antibiotics Needed For Drug-Resistant Infections, Acurx Pharmaceuticals May Have The Answers
Antibiotic resistant bacteria are increasing. Overuse/misuse of antibiotics have had dire consequences. No new classes of antibiotics have been developed in almost 40 years. Significant new government incentives are proposed. Acurx Pharmaceuticals is developing new drugs for antibiotic-resistant infections.CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$7m |
| Dec 31 2025 | US$729k | US$550k | -US$8m |
| Sep 30 2025 | n/a | n/a | -US$9m |
| Jun 30 2025 | n/a | n/a | -US$10m |
| Mar 31 2025 | n/a | n/a | -US$12m |
| Dec 31 2024 | US$1m | US$538k | -US$14m |
| Sep 30 2024 | n/a | n/a | -US$16m |
| Jun 30 2024 | n/a | n/a | -US$17m |
| Mar 31 2024 | n/a | n/a | -US$16m |
| Dec 31 2023 | US$1m | US$475k | -US$15m |
| Sep 30 2023 | n/a | n/a | -US$13m |
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | n/a | n/a | -US$12m |
| Dec 31 2022 | US$655k | US$475k | -US$12m |
| Sep 30 2022 | n/a | n/a | -US$11m |
| Jun 30 2022 | n/a | n/a | -US$13m |
| Mar 31 2022 | n/a | n/a | -US$14m |
| Dec 31 2021 | US$4m | US$364k | -US$13m |
| Sep 30 2021 | n/a | n/a | -US$11m |
| Jun 30 2021 | n/a | n/a | -US$8m |
| Mar 31 2021 | n/a | n/a | -US$5m |
| Dec 31 2020 | US$596k | US$277k | -US$5m |
| Dec 31 2019 | US$290k | US$267k | -US$6m |
Compensation vs Market: Dave's total compensation ($USD729.39K) is about average for companies of similar size in the US market ($USD659.85K).
Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.
CEO
Dave Luci (59 yo)
Mr. David P. Luci, also known as Dave, CPA, J.D. Esq. served as Chairman of the Board at AMERI Holdings, Inc. since August 16, 2018 until December 12, 2018.Mr. Luci is the Co-Founder of Acurx Pharmaceutic...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 8.4yrs | US$771.73k | 1.18% $ 81.1k | |
| Co-Founder | 8.4yrs | US$729.39k | 1.34% $ 91.8k | |
| Independent Director | 5yrs | US$57.50k | 0.032% $ 2.2k | |
| Independent Director | 5yrs | US$52.50k | 0.0018% $ 123.1 | |
| Independent Director | 5yrs | US$55.00k | 0.026% $ 1.8k | |
| Independent Director | 7.8yrs | US$45.00k | 0.17% $ 11.4k | |
| Scientific Advisor & Independent Director | 5yrs | US$40.00k | 0.032% $ 2.2k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data |
Experienced Board: ACXP's board of directors are considered experienced (5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 12:33 |
| End of Day Share Price | 2026/07/02 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Acurx Pharmaceuticals, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Antonio Arce | H.C. Wainwright & Co. |
| Matthew Keller | H.C. Wainwright & Co. |